tert-butyl 4-(1-ethoxy-1-oxopropan-2-ylidene)piperidine-1-carboxylate

Catalog No.: 
ACGTKV832
CAS No.: 
473837-03-5
Molecular Formula: 
C15H25NO4
Molecular Weight: 
283.37
tert-butyl 4-(1-ethoxy-1-oxopropan-2-ylidene)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$187.00InquiryInquiry
1g95%$537.00InquiryInquiry
5g95%$1611.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl 4-(1-ethoxy-1-oxopropan-2-ylidene)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-(1-ethoxy-1-oxopropan-2-ylidene)piperidine-1-carboxylate
Molecular FormulaC15H25NO4
Molecular Weight283.37
SMILESCCOC(=O)C(C)=C1CCN(C(=O)OC(C)(C)C)CC1
InChI KeyDBCYSDFJISJFLX-UHFFFAOYSA-N
Synonymtert-butyl 4-(1-ethoxy-1-oxopropan-2 -ylidene)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-(2-ethoxy-1-methyl-2-oxoethylidene)-, 1,1-dimethylethyl ester
CAS No.473837-03-5

Synthetic Route by SureRoute

1. ACGTKV832 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJHWY738 route compound structure diagram
    ACJHWY7383699-66-9In Stock
  4. Then
  5. ACGTKV832 route product structure diagram
    ACGTKV832473837-03-5
Inquiry

2. ACGTKV832 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFOCK507 route compound structure diagram
    ACFOCK5075717-37-3In Stock
  4. Then
  5. ACGTKV832 route product structure diagram
    ACGTKV832473837-03-5
Inquiry

3. ACGTKV832 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGTKV832 route product structure diagram
    ACGTKV832473837-03-5
Inquiry

Comments (0)